Butelman Eduardo R, Huang Yuefeng, McFarlane Alicia, Slattery Carolann, Goldstein Rita Z, Volkow Nora D, Alia-Klein Nelly
Neuropsychoimaging of Addictions and Related Conditions (NARC), Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Neuropsychoimaging of Addictions and Related Conditions (NARC), Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Drug Alcohol Depend. 2025 Feb 1;267:112535. doi: 10.1016/j.drugalcdep.2024.112535. Epub 2025 Jan 3.
The opioid epidemic causes massive morbidity, and males have substantially greater overdose mortality rates than females. It is unclear whether there are sex-related disparities at different stages in the trajectory of opioid use disorders (OUD), from large samples in the community.
To determine sex disparities in non-medical opioid use (NMOU) at the end of treatment with medications for opioid use disorder (MOUD), using national data.
Observational study of outpatient MOUD programs in the "Treatment episode data set-discharges" (TEDS-D) for 2019.
Persons aged ≥ 18 in their first treatment episode, in outpatient MOUD-based therapy for heroin or other opioids (N = 10,065). The binary outcome was presence/absence of NMOU in the month prior to discharge.
In univariate analyses, males had higher odds of NMOU compared to females (odds ratio=1.22; p = 6.84 ×10 after Bonferroni correction). A multivariable logistic regression detected a relatively small male>female odds ratio of 1.14 (p = 0.0039), surviving adjustment for demographic variables and social determinants of health. Several specific conditions were revealed in which males had greater odds of NMOU compared to females (e.g., if they were in the white racial category, and were not of hispanic ethnicity). Also, using by smoking, inhalation or injection routes (versus oral) was associated with greater odds of NMOU, irrespective of sex.
This national community sample shows that males overall have greater odds of NMOU in their first treatment episode with MOUD, a potential indicator of more unfavorable outcomes. Further analyses should examine the underpinnings of this disparity, including clinical severity features.
阿片类药物流行导致大量发病,男性的过量用药死亡率显著高于女性。目前尚不清楚在社区的大样本中,阿片类药物使用障碍(OUD)病程的不同阶段是否存在性别差异。
利用全国数据,确定在使用阿片类药物使用障碍药物(MOUD)治疗结束时,非医疗性阿片类药物使用(NMOU)中的性别差异。
对2019年“治疗事件数据集-出院”(TEDS-D)中的门诊MOUD项目进行观察性研究。
年龄≥18岁的首次治疗患者,接受基于门诊MOUD的海洛因或其他阿片类药物治疗(N = 10,065)。二元结局为出院前一个月是否存在NMOU。
在单变量分析中,男性出现NMOU的几率高于女性(优势比=1.22;经Bonferroni校正后p = 6.84×10)。多变量逻辑回归检测到相对较小的男性>女性优势比为1.14(p = 0.0039),在对人口统计学变量和健康的社会决定因素进行调整后仍然显著。研究发现了几种特定情况,其中男性出现NMOU的几率高于女性(例如,如果他们属于白人种族且非西班牙裔)。此外,无论性别如何,通过吸烟、吸入或注射途径(与口服相比)使用药物与出现NMOU的几率更高有关。
这个全国性社区样本表明,在首次接受MOUD治疗时,男性总体上出现NMOU的几率更高,这可能是更不利结局的一个潜在指标。进一步的分析应探讨这种差异的根源,包括临床严重程度特征。